Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies
Radiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient’s quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radi...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/7/925 |
id |
doaj-77558f5f2e0f41ab8b2880f7cebf7441 |
---|---|
record_format |
Article |
spelling |
doaj-77558f5f2e0f41ab8b2880f7cebf74412020-11-25T00:37:37ZengMDPI AGCancers2072-66942019-07-0111792510.3390/cancers11070925cancers11070925Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid BiopsiesDinesh K.R. Medipally0Thi Nguyet Que Nguyen1Jane Bryant2Valérie Untereiner3Ganesh D. Sockalingum4Daniel Cullen5Emma Noone6Shirley Bradshaw7Marie Finn8Mary Dunne9Aoife M. Shannon10John Armstrong11Fiona M. Lyng12Aidan D. Meade13Radiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandRadiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandRadiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandBioSpecT EA 7506, Université de Reims Champagne−Ardenne, UFR Pharmacie, 51097 Reims, FranceBioSpecT EA 7506, Université de Reims Champagne−Ardenne, UFR Pharmacie, 51097 Reims, FranceRadiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandClinical Trials Unit, St Luke’s Radiation Oncology Network, St Luke’s Hospital, D06 HH36 Dublin, IrelandClinical Trials Unit, St Luke’s Radiation Oncology Network, St Luke’s Hospital, D06 HH36 Dublin, IrelandClinical Trials Unit, St Luke’s Radiation Oncology Network, St Luke’s Hospital, D06 HH36 Dublin, IrelandClinical Trials Unit, St Luke’s Radiation Oncology Network, St Luke’s Hospital, D06 HH36 Dublin, IrelandCancer Trials Ireland, D11 KXN4 Dublin, IrelandCancer Trials Ireland, D11 KXN4 Dublin, IrelandRadiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandRadiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, D08 NF82 Dublin, IrelandRadiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient’s quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radiation toxicity. This study aimed to investigate the potential of Fourier transform infrared (FTIR) spectroscopy for monitoring radiotherapeutic response. Blood plasma was acquired from 53 prostate cancer patients at five different time points: prior to treatment, after hormone treatment, at the end of radiotherapy, two months post radiotherapy and eight months post radiotherapy. FTIR spectra were recorded from plasma samples at all time points and the data was analysed using MATLAB software. Discrimination was observed between spectra recorded at baseline versus follow up time points, as well as between spectra from patients showing minimal and severe acute and late toxicity using principal component analysis. A partial least squares discriminant analysis model achieved sensitivity and specificity rates ranging from 80% to 99%. This technology may have potential to monitor radiotherapeutic response in prostate cancer patients using non-invasive blood plasma samples and could lead to individualised patient radiotherapy.https://www.mdpi.com/2072-6694/11/7/925radiotherapytoxicityprostate cancerblood plasmahigh throughputFourier transform infrared spectroscopy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dinesh K.R. Medipally Thi Nguyet Que Nguyen Jane Bryant Valérie Untereiner Ganesh D. Sockalingum Daniel Cullen Emma Noone Shirley Bradshaw Marie Finn Mary Dunne Aoife M. Shannon John Armstrong Fiona M. Lyng Aidan D. Meade |
spellingShingle |
Dinesh K.R. Medipally Thi Nguyet Que Nguyen Jane Bryant Valérie Untereiner Ganesh D. Sockalingum Daniel Cullen Emma Noone Shirley Bradshaw Marie Finn Mary Dunne Aoife M. Shannon John Armstrong Fiona M. Lyng Aidan D. Meade Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies Cancers radiotherapy toxicity prostate cancer blood plasma high throughput Fourier transform infrared spectroscopy |
author_facet |
Dinesh K.R. Medipally Thi Nguyet Que Nguyen Jane Bryant Valérie Untereiner Ganesh D. Sockalingum Daniel Cullen Emma Noone Shirley Bradshaw Marie Finn Mary Dunne Aoife M. Shannon John Armstrong Fiona M. Lyng Aidan D. Meade |
author_sort |
Dinesh K.R. Medipally |
title |
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies |
title_short |
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies |
title_full |
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies |
title_fullStr |
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies |
title_full_unstemmed |
Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies |
title_sort |
monitoring radiotherapeutic response in prostate cancer patients using high throughput ftir spectroscopy of liquid biopsies |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-07-01 |
description |
Radiation therapy (RT) is used to treat approximately 50% of all cancer patients. However, RT causes a wide range of adverse late effects that can affect a patient’s quality of life. There are currently no predictive assays in clinical use to identify patients at risk of normal tissue radiation toxicity. This study aimed to investigate the potential of Fourier transform infrared (FTIR) spectroscopy for monitoring radiotherapeutic response. Blood plasma was acquired from 53 prostate cancer patients at five different time points: prior to treatment, after hormone treatment, at the end of radiotherapy, two months post radiotherapy and eight months post radiotherapy. FTIR spectra were recorded from plasma samples at all time points and the data was analysed using MATLAB software. Discrimination was observed between spectra recorded at baseline versus follow up time points, as well as between spectra from patients showing minimal and severe acute and late toxicity using principal component analysis. A partial least squares discriminant analysis model achieved sensitivity and specificity rates ranging from 80% to 99%. This technology may have potential to monitor radiotherapeutic response in prostate cancer patients using non-invasive blood plasma samples and could lead to individualised patient radiotherapy. |
topic |
radiotherapy toxicity prostate cancer blood plasma high throughput Fourier transform infrared spectroscopy |
url |
https://www.mdpi.com/2072-6694/11/7/925 |
work_keys_str_mv |
AT dineshkrmedipally monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT thinguyetquenguyen monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT janebryant monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT valerieuntereiner monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT ganeshdsockalingum monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT danielcullen monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT emmanoone monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT shirleybradshaw monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT mariefinn monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT marydunne monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT aoifemshannon monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT johnarmstrong monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT fionamlyng monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies AT aidandmeade monitoringradiotherapeuticresponseinprostatecancerpatientsusinghighthroughputftirspectroscopyofliquidbiopsies |
_version_ |
1725300403296272384 |